Levy AS1, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM J Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. Pediatr Hematol Oncol. 2013 Aug;35(6):456-61.
Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr Blood Cancer. 2013 Aug 17. doi: 10.1002/pbc.24656. [Epub ahead of print]
Eslin D, Sankpal U, Lee C, Sutphin R, Maliakal P, Currier E, Saulnier Sholler G, Khan M, and Basha R.. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog. 2013 May;52(5):377-86
Saulnier Sholler G, Ferguson W, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W, Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna G, Eugster E, Cherba D, Miller J, Webb C. A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of [...]
Sun Y, Shukla G, Pero SC, Currier E, Saulnier Sholler G, Krag D. Single tumor imaging with multiple antibodies targeting different antigens. Biotechniques. 2012 Apr;0(0):1-3.
Bachmann AS, Geerts D, Saulnier Sholler G: Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention, In: Pediatric Cancer, Volume 1, Neuroblastoma: Diagnosis, Therapy, and Prognosis, Ed. Hayat MA, Springer, Heidelberg, Germany, 2012
Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. 2013 Mar 2. doi: 10.1002/ijc.28139. [Epub ahead of print]
Koto K, Lescault P, Brard L, Kim K, Singh R, Bond J, Illenye S, Slavik M, Ashikaga T, Saulnier Sholler G. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int J Oncol. 2011, 38:1329-1341.
Singh R, Dorf L, DeMartino A, Illenye S, Koto K, Ashikaga T, Kwang Kim K, Brard L, Saulnier Sholler G. Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro. Cancer Biol Ther. 2011, 11:12, 1-10.
Saulnier Sholler G, Bergendahl G, Brard L, Singh AP, Heath B, Bingham P, Ashikaga T, Kamen B, Homans A, Slavik M, Lenox S, Higgins T, Ferguson W. A Phase I Study of Nifurtimox in Patients with Relapsed/Refractory Neuroblastoma. JPHO, 2011 Jan;33(1):25-30.
